InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Most read 2019: Antibody case law clearer in the US than Europe

Charlotte Kilpatrick, London


Pharma innovators say clearer standards on how monoclonal antibody patent applications are reviewed at the USPTO and US national courts have made it easier to file patents there than at the EPO

In-house sources at Sanofi, Bristol-Myers Squibb and a European pharma innovator say the differences in how the US and European patent offices and national courts review monoclonal antibody applications make filing patents clearer and safer in the former.

In Amgen...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

Most read articles

Latest Country Updates

Supplements